Capital Fund Management S.A. Agios Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.38 - $29.19 $229,535 - $313,383	10,736 Added 34.95%	41,455 $1.17 Million
Q1 2023 May 15, 2023	SELL	$21.74 - $30.93 $469,518 - $667,995	-21,597 Reduced 41.28%	30,719 $705,000
Q4 2022 Feb 13, 2023	BUY	$24.81 - $31.52 $968,632 - $1.23 Million	39,042 Added 294.12%	52,316 $1.47 Million
Q3 2022 Nov 14, 2022	BUY	$19.51 - $34.14 $258,975 - $453,174	13,274 New	13,274 $375 Million
Q4 2020 Feb 12, 2021	SELL	$33.21 - $46.54 $1.14 Million - $1.59 Million	-34,234 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$33.87 - $55.93 $687,323 - $1.13 Million	20,293 Added 145.56%	34,234 $1.2 Million
Q2 2020 Aug 13, 2020	SELL	$34.45 - $53.48 $129,669 - $201,298	-3,764 Reduced 21.26%	13,941 $745,000
Q4 2019 Feb 13, 2020	BUY	$30.08 - $50.59 $40,036 - $67,335	1,331 Added 8.13%	17,705 $845,000
Q3 2019 Nov 13, 2019	BUY	$32.4 - $49.58 $530,517 - $811,822	16,374 New	16,374 $531,000

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.84B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.